{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:39:51Z","timestamp":1787621991099,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["DFG 762\/3-2"],"award-info":[{"award-number":["DFG 762\/3-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neo.2024.101038","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T09:17:11Z","timestamp":1723281431000},"page":"101038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy"],"prefix":"10.1016","volume":"57","author":[{"given":"Hanna Elisabeth","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Maria","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Job","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Lankat-Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Gallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neo.2024.101038_bib0001","first-page":"39","article-title":"Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase \u03b1","volume":"8","author":"Abdel-Samad","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.neo.2024.101038_bib0002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/CAD.0000000000000511","article-title":"Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models","volume":"28","author":"Aouad","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.neo.2024.101038_bib0003","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.29886","article-title":"The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma","volume":"138","author":"Basma","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"33","key":"10.1016\/j.neo.2024.101038_bib0004","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","article-title":"Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells","volume":"274","author":"Boulares","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.neo.2024.101038_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.neo.2024.101038_bib0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neo.2024.101038_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104253","article-title":"Novel adamantyl retinoid-related molecules with POLA1 inhibitory activity","volume":"104","author":"Cincinelli","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neo.2024.101038_bib0008","doi-asserted-by":"crossref","first-page":"23784","DOI":"10.1038\/srep23784","article-title":"Human DNA polymerase \u03b1 in binary complex with a DNA:DNA template-primer","volume":"6","author":"Coloma","year":"2016","journal-title":"Sci. Rep."},{"issue":"5547","key":"10.1016\/j.neo.2024.101038_bib0009","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neo.2024.101038_bib0010","unstructured":"Anon. Cosmic. 2023. COSMIC - catalogue of somatic mutations in cancer. https:\/\/cancer.sanger.ac.uk\/cosmic. Accessed 9 April 2024."},{"key":"10.1016\/j.neo.2024.101038_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113971","article-title":"Antitumor activity of novel POLA1-HDAC11 dual inhibitors","volume":"228","author":"Dallavalle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neo.2024.101038_bib0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ijms241814069","article-title":"The antitumor effect of the DNA polymerase alpha inhibitor ST1926 in glioblastoma: a proteomics approach","volume":"24","author":"El-Baba","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.neo.2024.101038_bib0013","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.neo.2024.101038_bib0014","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.celrep.2020.01.067","article-title":"Physiological tolerance to ssDNA enables strand uncoupling during DNA replication","volume":"30","author":"Ercilla","year":"2020","journal-title":"Cell Rep."},{"issue":"7035","key":"10.1016\/j.neo.2024.101038_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neo.2024.101038_bib0016","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/stem.595","article-title":"Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction","volume":"29","author":"Gallmeier","year":"2011","journal-title":"Stem Cells (1981)"},{"issue":"5","key":"10.1016\/j.neo.2024.101038_bib0017","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4161\/cbt.6.5.3978","article-title":"Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer","volume":"6","author":"Gallmeier","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.neo.2024.101038_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.immuni.2016.01.020","article-title":"Caspases connect cell-death signaling to organismal homeostasis","volume":"44","author":"Galluzzi","year":"2016","journal-title":"Immunity."},{"issue":"7","key":"10.1016\/j.neo.2024.101038_bib0019","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.2082","article-title":"The antitumor toxin CD437 is a direct inhibitor of DNA polymerase \u03b1","volume":"12","author":"Han","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.neo.2024.101038_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nature Rev. Cancer"},{"issue":"6","key":"10.1016\/j.neo.2024.101038_bib0021","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.6857","article-title":"A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers","volume":"7","author":"Hocke","year":"2016","journal-title":"Oncotarget."},{"issue":"18","key":"10.1016\/j.neo.2024.101038_bib0022","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/sj.onc.1210049","article-title":"Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation","volume":"26","author":"Hurley","year":"2007","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.neo.2024.101038_bib0023","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.neo.2018.08.009","article-title":"Inactivation of PRIM1 function sensitizes cancer cells to ATR and CHK1 inhibitors","volume":"20","author":"Job","year":"2018","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.neo.2024.101038_bib0024","doi-asserted-by":"crossref","first-page":"18924","DOI":"10.1038\/s41598-020-76033-1","article-title":"The POLD1(R689W) variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors","volume":"10","author":"Job","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.neo.2024.101038_bib0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.neo.2024.101038_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389450118666170711151518","article-title":"PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials","volume":"19","author":"Kamel","year":"2018","journal-title":"Curr. Drug Targets."},{"issue":"5","key":"10.1016\/j.neo.2024.101038_bib0027","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ejso.2007.02.007","article-title":"Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability","volume":"33","author":"Kim","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2024.101038_bib0028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A Phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2024.101038_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J. ImmunOther Cancer"},{"issue":"38","key":"10.1016\/j.neo.2024.101038_bib0030","doi-asserted-by":"crossref","first-page":"28036","DOI":"10.1074\/jbc.M704635200","article-title":"The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR","volume":"282","author":"Lee","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neo.2024.101038_bib0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","article-title":"A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry","volume":"139","author":"Nicoletti","year":"1991","journal-title":"J. Immunol. Methods"},{"issue":"10","key":"10.1016\/j.neo.2024.101038_bib0032","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.neo.2024.101038_bib0033","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.neo.2024.101038_bib0034","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"RadiOther Oncol."},{"issue":"8","key":"10.1016\/j.neo.2024.101038_bib0035","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/0008-5472.CAN-19-1372","article-title":"CHK1 inhibition is synthetically lethal with loss of B-Family DNA polymerase function in human lung and colorectal cancer cells","volume":"80","author":"Rogers","year":"2020","journal-title":"Cancer Res."},{"issue":"27","key":"10.1016\/j.neo.2024.101038_bib0036","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.jchromb.2009.08.001","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study","volume":"877","author":"Sala","year":"2009","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"5","key":"10.1016\/j.neo.2024.101038_bib0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","article-title":"Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer","volume":"34","author":"Scagliotti","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.neo.2024.101038_bib0038","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1016119328968","article-title":"Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update","volume":"7","author":"Soldani","year":"2002","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.neo.2024.101038_bib0039","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2767-9764.CRC-22-0168","article-title":"Replication stress defines distinct molecular subtypes across cancers","volume":"2","author":"Takahashi","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.neo.2024.101038_bib0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4161\/cc.8.3.7661","article-title":"Replication stress activates DNA polymerase alpha-associated Chk1","volume":"8","author":"Taricani","year":"2009","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.neo.2024.101038_bib0041","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication catastrophe: when a checkpoint fails because of exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.neo.2024.101038_bib0042","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.neo.2024.101038_bib0043","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/1535-7163.MCT-08-0419","article-title":"Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity","volume":"7","author":"Valli","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2024.101038_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","article-title":"Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia","volume":"61","author":"Webster","year":"2017","journal-title":"Leuk. Res."},{"issue":"15","key":"10.1016\/j.neo.2024.101038_bib0045","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.neo.2024.101038_bib0046","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-06-0679","article-title":"Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival","volume":"6","author":"Wilsker","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2024.101038_bib0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/B978-0-12-385493-3.00004-8","article-title":"Apoptosis and beyond: cytometry in studies of programmed cell death","volume":"103","author":"Wlodkowic","year":"2011","journal-title":"Methods Cell Biol."},{"issue":"27","key":"10.1016\/j.neo.2024.101038_bib0048","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR Inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.neo.2024.101038_bib0049","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T03:07:19Z","timestamp":1729220839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":49,"alternative-id":["S1476558624000800"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101038","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101038"}}